Arcadia Biosciences, Inc. (RKDA) AI Stock Analysis

Arcadia Biosciences, Inc., based in Davis, California, produces and markets plant-based health and wellness products across the United States. Founded in 2002, the company develops crop improvements, primarily in wheat, designed to enhance farm economics by boosting crop performance and value as food ingredients. Arcadia applies biotechnology and breeding techniques to improve crop yield, quality, and resilience, aiming to create nutrient-rich crops for sustainable agricultural solutions. The company partners with food producers, health and wellness brands, and industrial entities to commercialize its agricultural science and plant-based innovations.

Between FY2020 and FY2025, Arcadia Biosciences recorded a 5-year revenue compound annual growth rate of -9.6%. Annual revenue moved from $6.8M in FY2021 to $4.9M in FY2025, with net income improving from -$14.7M to -$2.3M over the same period. Gross margin stood at 36.2% in FY2025, down from 41.3% in FY2024 and 51.2% in FY2023. Operating margin was -205.7% in FY2025. For the trailing twelve months ending June 30, 2026, revenue was $4.7M, operating margin was -34.4%, and diluted EPS was -$4.55. In the latest quarter ended June 30, 2026, quarterly revenue fell 0.8% year-over-year, while quarterly earnings grew 28.5%.

As of June 30, 2026, Arcadia Biosciences held $4.2M in cash and short-term investments out of $5.9M in total assets. Shareholders' equity was $633,000, and the current ratio was 3.49. The company has historically absorbed cash through operations, reporting operating cash flow of -$4.7M and free cash flow of -$4.7M in FY2025, though these improved from -$25.9M and -$26.9M, respectively, in FY2021. Research and development expenses were reduced from $3.9M in FY2021 to $9,000 in FY2025. Share count increased by 146.7% over the 5-year period.

At a last close of $0.17 on October 16, 2026, Arcadia Biosciences has a market capitalization of $397,037 and an enterprise value of -$3.4M. RKDA trades at a price-to-sales multiple of 0.1x compared to 0.7x for the median of its US-listed Consumer Defensive peers. Its forward price-to-earnings ratio is 36.6x, above the peer median of 14.3x. Enterprise value to EBITDA is 0.6x versus 11.7x for peers. Over the past year, RKDA fell 96.8%, compared to a 16.8% gain for the S&P 500 (SPY), and is down 99.8% over five years.

For next fiscal year, one analyst covers Arcadia Biosciences, projecting revenue of $7.7M (representing 29.3% growth) and an EPS estimate of -$2.42. The mean price target is $12.00, compared to the last close of $0.17. Over the last four quarters, the company beat EPS estimates twice. The next earnings date is November 6, 2026.

This page is an AI-written research summary of Arcadia Biosciences, Inc. (RKDA). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: RKDA income statement, RKDA balance sheet, RKDA key metrics, RKDA analyst forecast, RKDA chart. See the RKDA stock overview for the latest quote and news.